humana inc. - HUM
HUM
Close Chg Chg %
269.50 -5.16 -1.91%
Closed Market
264.34
-5.16 (1.91%)
Volume: 967.92K
Last Updated:
Mar 28, 2025, 3:59 PM EDT
Company Overview: humana inc. - HUM
HUM Key Data
| Open $270.88 | Day Range 263.41 - 271.68 |
| 52 Week Range 213.39 - 406.36 | Market Cap $32.63B |
| Shares Outstanding 120.69M | Public Float 120.43M |
| Beta 0.58 | Rev. Per Employee N/A |
| P/E Ratio 27.09 | EPS $10.00 |
| Yield 130.88% | Dividend $0.89 |
| EX-DIVIDEND DATE Mar 28, 2025 | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.35M |
HUM Performance
| 1 Week | -0.60% | ||
| 1 Month | -2.16% | ||
| 3 Months | 3.50% | ||
| 1 Year | -23.69% | ||
| 5 Years | -10.94% |
HUM Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
27
Full Ratings ➔
An error occurred while fetching the data.
An error occurred while fetching the data.
Snapshot
| Average Recommendation | HOLD | Average Target Price | 286.19 | |
| Number of Ratings | 27 | Current Quarters Estimate | 9.963 | |
| FY Report Date | 03 / 2025 | Current Year's Estimate | 16.366 | |
| Last Quarter’s Earnings | -2.16 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 16.21 | Next Fiscal Year Estimate | 13.822 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 23 | 23 | 25 | 23 |
| Mean Estimate | 9.96 | 6.18 | 16.37 | 13.82 |
| High Estimates | 10.92 | 8.34 | 17.00 | 16.75 |
| Low Estimate | 7.97 | 4.22 | 16.22 | 6.03 |
| Coefficient of Variance | 6.73 | 18.00 | 1.01 | 16.22 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 5 | 5 | 6 |
| OVERWEIGHT | 2 | 3 | 2 |
| HOLD | 19 | 17 | 18 |
| UNDERWEIGHT | 1 | 1 | 2 |
| SELL | 0 | 0 | 0 |
| MEAN | Hold | Hold | Hold |
SEC Filings for Humana Inc. - HUM
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Humana Inc. - HUM
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Feb 27, 2025 | Sanjay K. Shetty President, CenterWell | 11,566 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Michelle A. O'Hara Chief Human Resources Officer | 11,266 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Japan Mehta Chief Information Officer | 8,628 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Celeste Mellet Brown Chief Financial Officer | 29,676 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | John-Paul W. Felter SVP, Chief Accting Off & Cont. | 1,767 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Jim Rechtin President & CEO | 23,944 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | David Dintenfass President, Enterprise Growth | 16,234 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Vishal Agrawal Chief Strat & Corp Dev Officer | 16,717 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Vishal Agrawal Chief Strat & Corp Dev Officer | 13,447 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $258.58 per share | 3,477,125.26 |
| Feb 26, 2025 | Vishal Agrawal Chief Strat & Corp Dev Officer | 14,352 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 26, 2025 | David Dintenfass President, Enterprise Growth | 11,874 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $258.58 per share | 3,070,378.92 |
| Jan 10, 2025 | Jim Rechtin President & CEO | 4,907 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $264.68 per share | 1,298,784.76 |
| Jan 10, 2025 | Jim Rechtin President & CEO | 4,366 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 6, 2025 | Wayne A. I. Frederick Director | 2,408 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 6, 2025 | Marcy S. Klevorn Director | 25 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 6, 2025 | Marcy S. Klevorn Director | 2,005 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 6, 2025 | Wayne A. I. Frederick Director | 38 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Dec 18, 2024 | Sam Deshpande Chief Information Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Dec 18, 2024 | Sam Deshpande Chief Information Officer | 14,015 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $271.68 per share | 3,807,595.20 |
| Dec 18, 2024 | Sam Deshpande Chief Information Officer | 14,167 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
Humana Inc. in the News
Covid-19 charges at hospitals can vary by tens of thousands of dollars, a WSJ analysis finds
The cost of similar Covid-19 treatments can vary by tens of thousands of dollars a patient, even within the same hospital, according to a Wall Street Journal analysis of pricing data that indicates pandemic care hasn’t escaped the complex economics of the U.S. health system.
Stock futures trade mixed ahead of Fed decision
U.S. equity futures were pointing lower ahead of Wednesday's opening bell on Wall Street.